Published in J Virol on December 28, 2011
Orthopoxvirus targets for the development of new antiviral agents. Antiviral Res (2012) 0.81
Activation of stress response pathways promotes formation of antiviral granules and restricts virus replication. Mol Cell Biol (2014) 0.81
The master regulator of the cellular stress response (HSF1) is critical for orthopoxvirus infection. PLoS Pathog (2014) 0.78
Probing the virus host interaction in high containment: an approach using pooled short hairpin RNA. Assay Drug Dev Technol (2015) 0.75
Vaccinia reporter viruses for quantifying viral function at all stages of gene expression. J Vis Exp (2014) 0.75
Mapping short DNA sequencing reads and calling variants using mapping quality scores. Genome Res (2008) 157.44
The detection of monkeypox in humans in the Western Hemisphere. N Engl J Med (2004) 6.32
Poxviruses and immune evasion. Annu Rev Immunol (2001) 4.80
Kinesin-dependent movement on microtubules precedes actin-based motility of vaccinia virus. Nat Cell Biol (2001) 3.67
An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J Virol (2005) 3.36
Repulsion of superinfecting virions: a mechanism for rapid virus spread. Science (2010) 3.11
Ribonucleic acid synthesis in vaccinia virus. I. The mechanism of synthesis and release of RNA in vaccinia cores. J Mol Biol (1970) 3.08
Poxvirus tropism. Nat Rev Microbiol (2005) 3.07
Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A (2010) 2.69
Role of DNA replication in vaccinia virus gene expression: a naked template is required for transcription of three late trans-activator genes. Cell (1990) 2.53
Human monkeypox: an emerging zoonotic disease. Future Microbiol (2007) 2.15
Derepression of a novel class of vaccinia virus genes upon DNA replication. EMBO J (1988) 2.13
Vaccinia virus transcription. J Gen Virol (2003) 1.80
Vesicular stomatitis virus infection alters the eIF4F translation initiation complex and causes dephosphorylation of the eIF4E binding protein 4E-BP1. J Virol (2002) 1.78
Vaccinia virus morphogenesis and dissemination. Trends Microbiol (2008) 1.73
Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob Agents Chemother (2009) 1.52
Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin Microbiol Rev (2001) 1.47
ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob Agents Chemother (2009) 1.45
A successful eradication campaign. Global eradication of smallpox. Rev Infect Dis (1983) 1.44
A novel cellular protein, VPEF, facilitates vaccinia virus penetration into HeLa cells through fluid phase endocytosis. J Virol (2008) 1.41
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob Agents Chemother (2007) 1.38
Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice. J Virol (2006) 1.21
Superinfection exclusion of vaccinia virus in virus-infected cell cultures. Virology (1990) 1.19
Inhibition of host protein synthesis by vaccinia virus: fate of cell mRNA and synthesis of small poly (A)-rich polyribonucleotides in the presence of actinomycin D. J Virol (1975) 1.12
Killing a killer: what next for smallpox? PLoS Pathog (2010) 0.99
Smallpox and bioterrorism. N Engl J Med (2002) 0.93
Development of Vaccinia reporter viruses for rapid, high content analysis of viral function at all stages of gene expression. Antiviral Res (2011) 0.90
Orthopoxvirus targets for the development of antiviral therapies. Curr Drug Targets Infect Disord (2005) 0.90
An isatin-beta-thiosemicarbazone-resistant vaccinia virus containing a mutation in the second largest subunit of the viral RNA polymerase is defective in transcription elongation. J Biol Chem (2004) 0.88
Synthesis of vaccinia virus polypeptides in the presence of isatin-beta-thiosemicarbazone. Antimicrob Agents Chemother (1973) 0.83
Comparative whole genome sequence analysis of wild-type and cidofovir-resistant monkeypoxvirus. Virol J (2010) 0.81
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med (2005) 6.77
Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol (2003) 4.67
Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet (2010) 4.52
Effective post-exposure treatment of Ebola infection. PLoS Pathog (2007) 3.69
Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature (2011) 3.66
Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet (2003) 3.57
Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. MBio (2014) 3.49
Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis (2003) 3.33
Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet (2006) 3.15
Comprehensive panel of real-time TaqMan polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and New World hantaviruses. Am J Trop Med Hyg (2010) 2.92
Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A (2003) 2.82
Molecular Evidence of Sexual Transmission of Ebola Virus. N Engl J Med (2015) 2.71
Development of a new vaccine for the prevention of Lassa fever. PLoS Med (2005) 2.71
Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A (2010) 2.69
Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol (2003) 2.66
Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol (2008) 2.58
A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A (2010) 2.41
Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol (2009) 2.41
Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc Natl Acad Sci U S A (2004) 2.36
Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine (2008) 2.33
Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis (2006) 2.19
Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog (2008) 2.10
Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J Infect Dis (2007) 2.09
N-glycans on Nipah virus fusion protein protect against neutralization but reduce membrane fusion and viral entry. J Virol (2006) 1.97
The host response to smallpox: analysis of the gene expression program in peripheral blood cells in a nonhuman primate model. Proc Natl Acad Sci U S A (2004) 1.85
Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol (2006) 1.85
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A (2007) 1.76
Dissecting interferon-induced transcriptional programs in human peripheral blood cells. PLoS One (2010) 1.73
Interferon-alpha initiates type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A (2008) 1.66
Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis (2011) 1.62
FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med (2013) 1.62
Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Arch Virol (2012) 1.59
Capture and transfer of HIV-1 particles by mature dendritic cells converges with the exosome-dissemination pathway. Blood (2008) 1.58
An optofluidic nanoplasmonic biosensor for direct detection of live viruses from biological media. Nano Lett (2010) 1.57
Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques. Viral Immunol (2004) 1.55
Early days: genomics and human responses to infection. Curr Opin Microbiol (2006) 1.54
Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions. Expert Rev Mol Med (2004) 1.52
Pathologic findings associated with delayed death in nonhuman primates experimentally infected with Zaire Ebola virus. J Infect Dis (2007) 1.52
Seeing protein monolayers with naked eye through plasmonic Fano resonances. Proc Natl Acad Sci U S A (2011) 1.52
Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases. J Biol Chem (2003) 1.50
Polybasic KKR motif in the cytoplasmic tail of Nipah virus fusion protein modulates membrane fusion by inside-out signaling. J Virol (2007) 1.48
ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob Agents Chemother (2009) 1.45
In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein. J Infect Dis (2007) 1.43
Postexposure treatment of Marburg virus infection. Emerg Infect Dis (2010) 1.43
Murine B cell response to TLR7 ligands depends on an IFN-beta feedback loop. J Immunol (2009) 1.42
Cynomolgus macaque as an animal model for severe acute respiratory syndrome. PLoS Med (2006) 1.40
Comparative analysis of viral gene expression programs during poxvirus infection: a transcriptional map of the vaccinia and monkeypox genomes. PLoS One (2008) 1.37
Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis (2012) 1.32
Capacity building permitting comprehensive monitoring of a severe case of Lassa hemorrhagic fever in Sierra Leone with a positive outcome: case report. Virol J (2011) 1.29
Ebola virus genome plasticity as a marker of its passaging history: a comparison of in vitro passaging to non-human primate infection. PLoS One (2012) 1.28
The pathogenesis of Rift Valley fever virus in the mouse model. Virology (2010) 1.28
Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J Infect Dis (2012) 1.27
Welwistatin support studies: expansion and limitation of aryllead(IV) coupling reactions. J Org Chem (2007) 1.26
Evolution of ebola virus disease from exotic infection to global health priority, Liberia, mid-2014. Emerg Infect Dis (2015) 1.21
Filoviruses require endosomal cysteine proteases for entry but exhibit distinct protease preferences. J Virol (2012) 1.21
The temporal program of peripheral blood gene expression in the response of nonhuman primates to Ebola hemorrhagic fever. Genome Biol (2007) 1.20
Preferential translation of vesicular stomatitis virus mRNAs is conferred by transcription from the viral genome. J Virol (2006) 1.18
Label-free multiplexed virus detection using spectral reflectance imaging. Biosens Bioelectron (2011) 1.18
Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition. Cell Microbiol (2009) 1.16
Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae. Arch Virol (2013) 1.16
Lymphocyte death in a mouse model of Ebola virus infection. J Infect Dis (2007) 1.12
Real-time monitoring of cardiovascular function in rhesus macaques infected with Zaire ebolavirus. J Infect Dis (2011) 1.12
Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Arch Virol (2013) 1.10
Single nanoparticle detectors for biological applications. Nanoscale (2012) 1.10
Countermeasures to the bioterrorist threat of smallpox. Curr Mol Med (2005) 1.08
The neuronal actin-binding proteins, neurabin I and neurabin II, recruit specific isoforms of protein phosphatase-1 catalytic subunits. J Biol Chem (2002) 1.07
hnRNPs Relocalize to the cytoplasm following infection with vesicular stomatitis virus. J Virol (2008) 1.04
Inhibition of heat-shock protein 90 reduces Ebola virus replication. Antiviral Res (2010) 1.04
Development of a novel nonhuman primate model for Rift Valley fever. J Virol (2011) 0.99
Stunned silence: gene expression programs in human cells infected with monkeypox or vaccinia virus. PLoS One (2011) 0.98
Cellular immune response to Marburg virus infection in cynomolgus macaques. Viral Immunol (2008) 0.96
Presence of broadly reactive and group-specific neutralizing epitopes on newly described isolates of Crimean-Congo hemorrhagic fever virus. J Gen Virol (2005) 0.96
Therapeutics of Ebola hemorrhagic fever: whole-genome transcriptional analysis of successful disease mitigation. J Infect Dis (2011) 0.96
Evaluation of Lassa antiviral compound ST-193 in a guinea pig model. Antiviral Res (2011) 0.94
Akt inhibitor Akt-IV blocks virus replication through an Akt-independent mechanism. J Virol (2009) 0.94
Potential vaccines and post-exposure treatments for filovirus infections. Viruses (2012) 0.94
The NIAID Integrated Research Facility at Frederick, Maryland: a unique international resource to facilitate medical countermeasure development for BSL-4 pathogens. Pathog Dis (2014) 0.93
Structural characterization of an enantiomerically pure amino acid imidazolide and direct formation of the beta-lactam nucleus from an alpha-amino acid. Org Lett (2008) 0.93
Integrin alphaIIbbeta3:ligand interactions are linked to binding-site remodeling. Protein Sci (2006) 0.92
Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever. Virol J (2010) 0.92
Dominant inhibition of Akt/protein kinase B signaling by the matrix protein of a negative-strand RNA virus. J Virol (2010) 0.91
Aerosol exposure to Rift Valley fever virus causes earlier and more severe neuropathology in the murine model, which has important implications for therapeutic development. PLoS Negl Trop Dis (2013) 0.91
Development of Vaccinia reporter viruses for rapid, high content analysis of viral function at all stages of gene expression. Antiviral Res (2011) 0.90
Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections. Virology (2002) 0.90
Network-based prediction for sources of transcriptional dysregulation using latent pathway identification analysis. Proc Natl Acad Sci U S A (2011) 0.90
Myxoma and vaccinia viruses bind differentially to human leukocytes. J Virol (2013) 0.90
HijAkt: The PI3K/Akt pathway in virus replication and pathogenesis. Prog Mol Biol Transl Sci (2012) 0.89
Progression of pathogenic events in cynomolgus macaques infected with variola virus. PLoS One (2011) 0.87
Transcriptional profiling of the circulating immune response to lassa virus in an aerosol model of exposure. PLoS Negl Trop Dis (2013) 0.87
Ebola virus exploits a monocyte differentiation program to promote its entry. J Virol (2013) 0.86
Vesicular stomatitis virus matrix protein mutations that affect association with host membranes and viral nucleocapsids. J Biol Chem (2008) 0.86